Previous 10 | Next 10 |
home / stock / sttk / sttk articles
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The ...
U.S. stocks traded higher midway through trading, following the release of PPI data on Wednesday. The Dow traded up 0.06% to 36,598.24 while the NA...
Shattuck Labs Inc (NASDAQ: STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination w...
AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology compan...
AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology comp...
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology compa...
– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability pr...
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with ...
Gainers FaZe Holdings Inc. (NASDAQ: FAZE) shares rose 64.7% to $0.2520 in pre-market trading after falling over 4% on Friday. Biophytis S.A. (NAS...
News, Short Squeeze, Breakout and More Instantly...
Shattuck Labs Inc. Company Name:
STTK Stock Symbol:
NASDAQ Market:
2024-06-14 19:15:01 ET BTIG analyst issues NEUTRAL recommendation for STTK on June 14, 2024 05:34PM ET. STTK was trading at $6.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontli...
AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmun...